BioNexus Gene Lab Corp BGLC

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malay…

The label

Distribution

read at $1.66

BioNexus Gene Lab Corp holds its Distribution at $1.66.

PHPhase · the trend structure carries the Distribution label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate

edge confirmed
edge broken
edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-12-31
Phase	Distribution · caution
Quantitative state	The statistical read favours the sellers, held for 162 days
Price	$1.66
Valuation	N/A trailing · N/A forward price to earnings
Values screen	PASS · score 70.0
Beta	2.21

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Revenue growth	-98.9% revenue is shrinking
Profit margin	-54.7% currently unprofitable
Return on equity	-36.6% not currently earning a positive return on equity
Debt to equity	4.28 heavy leverage — higher risk if revenue softens
Current ratio	6.52 comfortably covers its short-term bills
Beta	2.21 much more volatile than the market
Market cap	$4M
Employees	19

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to Malaysia and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in BGLC's space worth a look

CNEY CN Energy Group Inc SNES SenesTech Inc YMAT J-Star Holding Co Ltd BON Bon Natural Life Ltd FEAM 5E Advanced Materials Inc FSI Flexible Solutions International, Inc.

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 22.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. Entered 2026-07-23 · Accumulation

The dated journal · newest first, never edited

2026-07-23 Accumulation $1.66 -22.4% Entry 4

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 22.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%.

2026-07-18 Accumulation $2.14 +0.0% Entry 3

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%.

2026-07-03 Accumulation $2.14 +0.0% Entry 2

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Accumulation $2.14 Entry 1

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
Period	Price then	Price return	Divs per share	$1,000 became	Total return
1 month	$2.06	+3.4%	·	$1,034	+3.4%
2 months	$2.18	-2.3%	·	$977	-2.3%
3 months	$2.23	-4.5%	·	$955	-4.5%
6 months	$4.26	-50.0%	·	$500	-50.0%
1 year	$3.14	-32.2%	·	$678	-32.2%
2 years	$5.30	-59.8%	·	$402	-59.8%
3 years	$33.24	-93.6%	·	$64	-93.6%
5 years	$220.80	-99.0%	·	$10	-99.0%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever BGLC does next, these words stay.

BioNexus Gene Lab Corp · BGLC · Distribution · $1.66
Recorded 2025-12-31 · before the outcome · scored mechanically

All of today's entries See the running score

BioNexus Gene Lab Corp BGLC

This entry now belongs to the ledger. Whatever BGLC does next, these words stay.

Before you go